Dose-Adjusted Beta-Lactam Antibiotic-Induced Encephalopathy in a Patient with End-Stage Renal Impairment: A Case Report by Anthony, Chris et al.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2015_000172 European Journal of Case Reports in Internal Medicine © EFIM 2015
Doi: 10.12890/2015_000172 - European Journal of Case Reports in Internal Medicine - © EFIM 2015
Dose-Adjusted Beta-Lactam Antibiotic-Induced Encephalopathy in a Patient with End-Stage 
Renal Impairment: A Case Report
Chris Anthonya, Meenal Sharmaa, Roberto Spinaa, Peter S Macdonalda, Jacob Sevastosb
aDepartment of Cardiology, St Vincent’s Hospital, Sydney, Australia
bDepartment of Nephrology, St Vincent’s Hospital, Sydney, Australia
Received: 16/12/2014
Accepted: 06/01/2015
Published: 11/02/2015
How to cite this article: Anthony C, Sharma M, Spina R, Macdonald PS, Sevastos J. Dose-adjusted beta-lactam antibiotic-induced encephalopathy in a 
patient with end-stage renal impairment: a case report. EJCRIM 2015;2:doi: 10.12890/2015_000172
Conflicts of Interests: The authors declare that they have no conflicts of interest in this research
This article is licensed under a Commons Attribution Non-Commercial 4.0 License
ABSTRACT
Introduction: Despite adherence to current guidelines regarding dose adjustment and drug-level monitoring, beta-lactam-induced 
encephalopathy can still occur in the setting of chronic renal impairment.
Case Report: We report what we believe is the first case of piperacillin- and tazobactam-induced encephalopathy in a patient with pre-existing 
cefepime-induced encephalopathy in the context of end-stage kidney disease despite adequate dose adjustment for renal impairment.
LEARNING POINTS
• Beta-lactam antibiotics may result in acute encephalopathy in susceptible patients.
• Patients with renal impairment are especially vulnerable to beta-lactam-induced encephalopathy.
• Appropriate renal adjustment of dosing may still result in the development of encephalopathy in patients with renal impairment.
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INTRODUCTION
Beta-lactam antibiotics given intravenously to patients with renal impairment can result in neurotoxicity that manifests as an acute decrease 
in consciousness, myoclonic jerks and seizure-type activity including non-convulsive status epilepticus[1–12]. Chronic kidney disease affects 
the drug elimination of beta-lactams and pharmacokinetic processes involved in its clearance. This makes the alteration of drug dosing with 
respect to individual creatinine clearance necessary[13]. Despite adherence to current guidelines regarding dose adjustment and drug-level 
monitoring, beta-lactam-induced encephalopathy can still occur in the setting of chronic renal impairment[5,7].
We report what we believe is the first case of piperacillin- and tazobactam-induced encephalopathy in a patient with pre-existing cefepime-
induced encephalopathy in the context of end-stage kidney disease despite adequate dose adjustment for renal impairment.
CASE REPORT
A 45-year-old female with a complex history of teenage ovarian and thyroid malignancy requiring chemo-radiotherapy, restrictive 
cardiomyopathy and end-stage chronic kidney disease requiring long-term peritoneal dialysis presented to our institution with severe 
hospital-acquired pneumonia and a functional ileus leading to multisystem organ dysfunction requiring intensive care admission. A year 
prior to this admission, she had a documented episode of acute encephalopathy post-cefepime initiation for a lower respiratory tract 
infection. Her creatinine at time of admission was 410 mmol/l with urea of 22.6 mmol/l. She was on a twice daily exchange regimen with 
2.5% icodextrin solution as part of her peritoneal dialysis regimen. She was commenced on piperacillin and tazobactam at a renally adjusted 
dose of 4.5 g bd for a period of 5 days, when she began to experience fluctuations in her conscious state with a recorded Glasgow Coma 
Scale of 12. At this point, the piperacillin and tazobactam were ceased and a subsequent level for the antibiotic was ordered. On Day 2, her 
piperacillin level was 445 mg/l, Day 3 130 mg/l, Day 4 9 mg/l and Day 5 1.5 mg/l. Her tazobactam levels were 62.3, 15.5 mg/l, 1.5 mg/l and 
0.5 mg/l on those days.
She was also transitioned onto continuous venovenous haemodiafiltration at this point to help facilitate drug clearance. Her cognitive state 
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continued to deteriorate and 24 h later her GCS had dropped to 3, requiring urgent intubation. Her encephalopathy persisted, with a failure 
to extubate her on Day 5 post-onset of encephalopathy. Unfortunately, she deteriorated further and succumbed to her illness on Day 10 of 
her ICU admission.
DISCUSSION
In patients with renal failure, penicillin- and cephalosporin-based antibiotics can accumulate in both the blood and cerebrospinal fluid, 
reaching toxic concentrations[1,2,4,14]. Current practice advocates dose-related adjustment of both penicillin and cefepime based on standard 
algorithms derived from individual creatinine clearance[13]. In this case, we made the appropriate renal dose adjustment prior to dosing of 
her penicillin-based antibiotic, however encephalopathy was still induced. This has been documented in several other studies, where dose-
related adjustment still induced neurological side effects post-administration[1–4]. Another interesting point is that there appeared to be no 
temporal relationship between previous exposure to piperacillin and tazobactam and the development of her encephalopathy, as she had 
received similar renal adjusted doses in the past without similar detrimental effects. This may be related to the degree of residual renal 
function impacting the risk of neurotoxicity, however there are no active assays to quantify this risk based on serum drug concentration[6].
Penicillin and piperacillin with tazobactam-induced encephalopathy has been documented in the literature, however less extensively than 
cefepime-induced encephalopathy[7,8,10–19]. A study by Chapuis et al.[16] looked prospectively at patients in intensive care who received renally 
adjusted doses of cefepime based on their calculated creatinine clearance and demonstrated that the plasma cefepime concentrations varied 
by two- to three-fold at peak levels and up to 40-fold at trough levels. This is potentially why our patient developed acute encephalopathy 
with cephalosporin use despite active measurement of her cefepime levels. In another retrospective review, of 100 patients in a critical 
care setting requiring cefepime intravenously, Fugate et al. showed that 29% developed neurologic symptoms despite a standard dose 
reduction based on their creatinine clearance[5]. Cefepime and its potential to reduce seizure threshold in patients with renal impairment 
was specifically emphasized in a United States Food and Drug Administration safety announcement in 2012[15] due to approximately 60 
cases of cefepime-associated non-convulsive status epilepticus and ongoing seizure activity that resulted in the death of at least 1 of those 
reported. This emphasizes the difficulty in predicting adverse outcomes even with appropriate pharmacokinetic dose adjustment in patients 
with pre-existing renal impairment with the use of cefepime[7,14].
Of note, neurotoxicity can also occur despite concurrent haemodialysis[14,16,18]. One would expect the neurological symptoms to improve 
after adequate clearance of the drug if on renal replacement therapy, as was the case with our patient, however predicting which groups of 
patients may develop encephalopathy and when remains entirely elusive.
CONCLUSION
Beta-lactam neurotoxicity affects patients critically ill with chronic kidney disease. It most commonly occurs when dose adjustments 
according to creatinine clearance are not performed, but can occur despite dose adjustment and renal replacement therapy in some patients, 
as described in this case, with significant detrimental effects. A more accurate method of measuring serum penicillin and cefepime levels is 
required to prevent the development of beta-lactam-induced encephalopathy, especially in patients with impaired renal function.
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